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Preeclampsia is a major cause of maternal and neonatal
morbidity and mortality. In mouse models, complement
activation in the placenta is associated with abnormal
placental development and miscarriage, and inhibiting
complement prevents fetal injury. We mated two mouse
strains, DBA/2 and CBA/J, expecting that the pregnancies
might show features of preeclampsia and of immunologically
mediated pregnancy loss. Along with placental dysfunction,
these matings resulted in proteinuria, elevated BUN, fibrin
deposition, and glomerular endotheliosis. We blocked
placental complement activation throughout pregnancy by
administering a single dose of the C3 inhibitor CR2-Crry
given on day 5 of the pregnancy. This procedure specifically
targets the sites of complement activation without inducing
any systemic effects. Placental complement inhibition
prevented oxidative stress and placental dysfunction, as well
as proteinuria and renal pathologic features of preeclampsia.
Thus, local blockade of complement activation at the
maternal–fetal interface rescues preeclampsia in mice, and
identifies new treatments. Hence, complement triggers a
feed-forward cycle of placental damage, antiangiogenic
factor production, and maternal vascular damage in patients.
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Preeclampsia is a major cause of maternal and neonatal
morbidity and mortality.1 Although typically diagnosed with
the onset of clinical manifestations, proteinuria and hyper-
tension after 20 weeks’ gestation, the syndrome begins much
earlier in pregnancy with abnormal placental development.
Uterine spiral arteries fail to remodel into dilated, flaccid
vessels, which results in underperfusion of the intervillous
space and placental hypoxia.2 Placental oxidative stress and
inflammation lead to the release of antiangiogenic factors
into the maternal circulation.3–5 Clinical manifestations,
widespread endothelial cell dysfunction presenting as protei-
nuria, hypertension, hemolysis, elevated liver enzymes, low
platelet counts (HELLP syndrome), and/or seizures, represent
the maternal response to this excess of antiangiogenic
factors.6 One such antiangiogenic factor is soluble fms-like
tyrosine kinase 1 (sFlt-1), a secreted splice variant of vascular
endothelial growth factor (VEGF) receptor-1 that sequesters
circulating VEGF and placental growth factor and prevents
their interaction with endogengous receptors.7 Elevated levels
of sFlt-1 are found in the circulation of pregnant women
destined for preeclampsia.8 Patients with cancer, who are
treated with inhibitors of VEGF often develop proteinuria
(21–64%) and may develop hypertension (3–36%)9 supports
this pathogenic mechanism.
We and others have suggested a relationship between the
activation of the complement system and angiogenic factor
imbalance linked to the placental dysfunction.10,11 In mouse
models, complement deposition in the placenta is associated
with the abnormal placental development and miscarriage,
while inhibiting complement rescues pregnancies.12,13 In
patients, complement activation localizes to villous tropho-
blast injury in vivo and modulates trophoblast function
in vitro.14 Preeclamptic placentas are characterized by
the marked deposition of terminal complement complex
(C5b-9).12 Our finding, that women with evidence of
activation of the alternative pathway early in pregnancy are
at increased risk for preeclampsia, suggests that complement
contributes to the disease pathogenesis.11 Finally, recent
reports of severe preeclampsia in patients with genetic defects
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in complement regulation, taken together with observation
that complement regulatory proteins are highly expressed on
trophoblasts, emphasize the importance of complement to
this syndrome.15,16
We considered the potential of complement inhibitor
therapy to prevent preeclampsia in those at high risk, but
were concerned that the prolonged systemic inhibition of
complement interferes with host defense. Novel complement
therapeutics that are targeted to the sites of complement
activation provide an alternative approach17 with limited
immunosuppression, improved bioavailability, and enhanced
efficacy in the experimental models of ischemia-reperfusion
injury, arthritis, and lupus.18–20 Whether this strategy could
be successful in preeclampsia depends on how important
complement activation at the maternal–fetal interface early in
pregnancy is to the placental dysfunction, angiogenic
dysregulation, and consequent maternal syndrome later in
pregnancy. We address this question in an experimental
model of preeclampsia triggered by immune and inflamma-
tory mediators.
DBA/2-mated CBA/J mice are well studied as a model of
immunologically mediated pregnancy loss that shares
features with human recurrent miscarriage.10,21 We have
shown that these matings are characterized by angiogenic
dysregulation manifested as elevated levels of circulating
sFlt-1, abnormal placental development, and fetal growth
restriction, and that systemic complement inhibition reverses
angiogenic imbalance, histological changes in placenta, and
prevents fetal injury.10 Because the maternal manifestations
of preeclampsia, most notably proteinuria and hypertension,
are mediated in part by antagonism of VEGF signaling
by sFlt-1 produced by the placenta as a consequence of
ischemia and inflammation,4,7 we hypothesized that CBA/J
DBA/2 matings would demonstrate features of preeclamp-
sia and reveal mediators and mechanisms that activate the
vicious cycle of placental damage, antiangiogenic factor
production, and maternal vascular damage in patients.
In this report, we provide the first evidence that DBA/2-
mated CBA/J pregnancies have characteristics of human
preeclampsia, including placental and renal manifestations.
We show that targeted complement inhibition early in
pregnancy in this mouse model prevents the placental and
later maternal syndrome, and that such a therapy is as effective
as administering VEGF to restore angiogenic balance.
RESULTS
Features of preeclampsia in CBA/JDBA/2 matings
In initial studies, we compared placental and maternal
phenotypes of DBA/2-mated CBA/J mice with control
matings, BALB/c-mated CBA/J (Table 1). In CBA/JDBA/
2 mice, weight of surviving fetuses was decreased, fetal/
placental weight ratios were reduced, and fetal resorptions
were increased, consistent with the alterations in placental
development we previously described.10 These abortion-
prone matings had elevated levels of circulating sFlt-1 as early
as day 7 of pregnancy (Table 1), which continued to increase
throughout the pregnancy and remained higher than CBA/J
BALB/c (Po0.05) until day 15 when mice were killed.
CBA/JDBA/2 mice had increased levels of placental
isoprostane 8-iso-prostaglandin F2a (STAT-8, a marker of
oxidative stress associated with impaired trophoblast inva-
sion) and elevated circulating thrombin–antithrombin III
complexes (TAT, a marker of activation of coagulation
cascade increased in microvascular injury) confirming
our previous studies (Table 1). Findings similar to those
detailed in Table 1 have been described in patients with
preeclampsia.22,23
To determine whether DBA/2-mated CBA/J mice develop
the maternal features of preeclampia, we assessed renal
function and kidney histopathology. Urinary protein and
blood urea nitrogen (BUN) on day 15 of pregnancy (mid
trimester) were higher in CBA/JDBA/2 mice compared
with CBA/JBALB/c mice (urine albumin/creatinine ratio:
359±102 versus 166±24 mg/mg, n¼ 10/group, Po0.05;
BUN: 73±7 versus 57±5 mg/dl, n¼ 14–16, Po0.05; Table 1
and Figure 1a and b). In grouped studies, 50% of CBA/J
DBA/2 mice had albumin/creatinine ratios greater than the
mean level of CBA/JBALB/c matings. Proteinuria tended
to be related to the placental function, as defined by mean
fetal weight at day 15 (Pearson r¼0.6, n¼ 10 mice;
P¼ 0.068). Immunofluorescence studies of kidneys showed
diffuse fibrin deposition within glomerular capillary walls
and lumina in CBA/JDBA/2 mice (mean fibrin score 1.5þ
range 1–2þ ) compared with CBA/JBALB/c (mean fibrin
score 0.25þ ; range 0–0.5þ ), a finding described in patients
with preeclampsia (Figure 1c). No glomerular intracapillary
fibrin thrombi were detected by light microscopy. Electron
microscopy revealed focal glomerular endothelial cell body
swelling consistent with ‘endotheliosis’ associated with
segmental foot process effacement (Figure 1d). No glomer-
ular intracapillary fibrin tactoids were identified. This
constellation of renal pathological findings was not present
in CBA/2BALB/c matings and represents the classic
findings in human preeclampsia.24–26
Table 1 | Features of preeclampsia in CBA/JDBA/2 matingsa
Mice/
group
CBA/
JDBA/2
CBA/
JBALB/c P-value
Placental function
Fetal weight (mg) 20–26 288±3 314±5 o0.0001
Fetal/placenta ratio (mg/mg) 20–26 2.4±0.05 2.7±0.05 o0.0001
Fetal resorption frequency (%) 20–26 23±4 7±4 o0.0025
STAT-8 (pg/ml) 21–22 171±24 121±14 o0.04
Maternal syndrome
sFlt-1 (pg/ml) 4 1454±137 425±56 o0.0004
TAT (mg/l) 5 93±27 32±14 o0.05
Urine albumin/creatinine (mg/mg) 10 359±102 166±24 o0.05
Blood BUN (mg/dl) 14–16 73.2±6.9 57.1±5.3 o0.04
Abbreviations: BUN, blood urea nitrogen; sFlt-1, fms-like tyrosine kinase 1; TAT,
thrombin–anti-thrombin III.
aAll assessments were performed on samples obtained on day 15 of pregnancy,
except sFlt-1, which was measured on day 7 of pregnancy.
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Figure 1 |CBA/JDBA/2 mice develop kidney damage, which is attenuated by targeted inhibition of complement. Pregnant
CBA/JDBA/2 mice were treated with CR2-Crry (200 mg i.v. on day 5 of pregnancy), VEGF121 (4 mg s.c. daily from day 3 to day 10 of
pregnancy), anti-mouse C5mAb (1mg i.p. on day 4 and day 6 of pregnancy) or PBS as control. On day 15 of pregnancy, urine and blood was
collected to measure albumin/creatinine ratios and BUN, mice were killed and kidneys removed. CBA/JDBA/2 matings resulted in
proteinuria (a) and elevated BUN levels (b), both of which were prevented by CR2-Crry, anti-C5mAb, and restoration of VEGF (n¼ 4–16 mice
per group). Mean and s.e.m. are shown. *Po0.05, **Po0.01. (c) Deposition of fibrin in glomeruli was assessed by immunofluorescence
staining and graded from 0–3þ . There was diffuse glomerular capillary wall and luminal staining in CBA/2DBA/J mice. Mean fibrin scores
(range): CBA/J BALB/c¼ 0.25þ (0–0.5þ ), CBA/JDBA/2¼ 1.5þ (1–2þ ), and CBA/JDBA/2 with CR2-Crry¼ 0.75þ (0.5–1þ ). Two fields
from each condition are shown (magnification  400 upper panel and  600 lower panel). Staining outside the glomeruli is in the
distribution of interstitial capillaries and was not significantly different between the samples. (d) Electron microscopic analysis of kidneys
from CBA/JDBA/2 mice showed endothelial cell swelling (blue arrowhead) with marked narrowing of the capillary lumen (ii and v) and
segmental areas of foot process effacement (red asterisk), which was not present in CBA/J BALB/c mice and which was ameliorated in
mice treated with CR2-Crry. i–iii, Magnification  8000; iv–vi, magnification  10,000. BUN, blood urea nitrogen; CR2, complement receptor
type 2; Crry, CR2-related gene/protein y; ec, endothelial cell; fp, foot process; mAb, monoclonal antibody; mc, mesangial cell;
PBS, phosphate-buffered saline; pc, patent capillary; VEGF, vascular endothelial growth factor.
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To determine whether pregnancy causes hypertension in
the CBA/JDBA/2 crosses, arterial pressures of CBA/J mice
were recorded with surgically implanted radiotelemeters
24 h/day beginning 3 days before mating and continuing
through delivery. Mean arterial blood pressure calculated for
19 CBA/JDBA/2 matings and 9 CBA/JBALB/c matings
were not different throughout pregnancy (Figure 2a). We
considered the possibility that mice with severe placental
dysfunction would become hypertensive and performed a
subset analysis comparing blood pressure in the most
divergent groups of mice defined by litter size, a proxy for
placental function, because blood pressure was monitored.
We compared mean arterial blood pressure in DBA/2
mated-CBA/J mice with fewer than five offspring to that of
BALB/c-mated CBA/J mice with greater than seven offspring
and again found no differences between the groups
(Figure 2b). Although a hallmark of human preeclampsia,
other informative genetic mouse models with reduced
spiral artery modification and placental dysfunction also fail
to develop hypertension27,28 and 10–15% of patients
with the most severe forms of preeclampsia are not
hypertensive.29 The strong evidence for placental dysfunc-
tion, taken together with our new findings of renal
manifestations characteristic of preeclampsia, identify CBA/
JDBA/2 mice as a new model to explore underlying
events that trigger some, but not all, cardinal features of
preeclampsia.
Targeted inhibitor of complement activation prevents
oxidative stress and placental dysfunction in CBA/JDBA/2
matings
To determine whether there was systemic evidence for
complement activation early in pregnancy, we measured
blood levels of C3a, a marker of classical or alternative
pathway activation, between days 3 and 7. Circulating C3a
was significantly higher in CBA/2DBA/J compared with
CBA/2BALB/c matings (422±43 versus 315±34, n¼ 9–10
mice/group, Po0.05), at a time when there was no evidence
of complement activation in the kidney (Figure 3, right
panels).
We have previously shown that excessive complement
activation occurs at the maternal–fetal interface of the
developing placenta by day 8 of pregnancy10 and confirmed
these findings in the current study (Figure 3, left panel). To
determine whether blocking complement activation in the
developing placenta early in pregnancy would prevent
features of preeclampsia in DBA/2-mated CBA/J mice, we
treated mice with CR2-Crry, a complement inhibitor
specifically targeted to sites of complement activation that
provides highly effective local protection without significant
systemic inhibition.17,18,30 CR2-Crry is composed of the
complement receptor type 2 (CR2)-binding site for cell-
bound C3 degradation products (iC3b/C3d) linked to the
complement regulatory protein domain of the murine
protein CR2-related gene/protein y (Crry), a murine C3
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Figure 2 |Blood pressure during pregnancy of CBA/JDBA/2 and CBA/JBALB/c mice. Female CBA/J mice implanted with telemeters
were mated with male DBA/2 or BALB/c mice. The 24 h MAP was monitored throughout pregnancy. Baseline reflects MAP over 3 days
before the pregnancy. The number of pups was recorded upon delivery. (a) Litter size and MAP for all pregnancies studied
(CBA/JDBA/2, n¼ 19 and CBA/J BALB/c, n¼ 9). (b) Results of pregnancies for selected mice based on litter size
(CBA/JDBA/2 with o5 pups, n¼ 7 and CBA/J BALB/c with 47 pups, n¼ 5; Po0.0001). MAP, mean arterial pressure;
NS, not significant.
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convertase inhibitor that blocks all complement activation
pathways.31 A single dose of CR2-Crry (0.2 mg) administered
i.v. on day 5 of pregnancy prevented complement deposition
(Figure 3, left panels) and placental dysfunction characteristic
of CBA/2DBA/J matings (Figure 4). In mice treated with
CR2-Crry, there was no increase in placental STAT-8, a
measure of oxidative stress associated with pregnancy
complications23,32,33 (Figure 4a), and no increase in the
circulating levels of the antiangiogenic factor sFlt-1 (Figure 4b).
Levels of sFlt-1 in CBA/2DBA/J mice treated with CR2-Crry
on day 5 were comparable with CBA/2BALB/c matings and
remained lower than untreated CBA/2DBA/J matings
through day 15, when the mice were killed (Po0.03). Similarly,
in CR2-Crry-treated mice there was no elevation in plasma
TAT levels on day 15 of pregnancy (Figure 4c).
As predicted by the measures of improved placental
function in CBA/2DBA/J mice, CR2-Crry prevented
increased fetal resorption characteristic of these matings
(Figure 4d). Fetal weights in CR2-Crry-treated pregnancies
increased slightly (control versus CR2-Crry: 288±3 versus
294±4 mg, n¼ 14–28, P¼ not significant). Studies of CR2-
Crry in other experimental models show accumulation of the
inhibitor at sites of tissue iC3b/C3d deposition and
prolonged tissue half-life consistent with CR2 domain-
mediated binding to tissue ligands.17–19 Taken together with
our previous report of C3 degradation fragments in the
decidua and ectoplacental cone of DBA/J-mated CBA/2
mice,10 the current findings indicate that early in pregnancy
complement inhibition localized exclusively to the maternal–
fetal interface is sufficient to prevent placental dysfunction
and poor pregnancy outcomes associated with preeclampsia.
Blockade of complement activation prevents proteinuria and
maternal features of preeclampsia
Given that maternal manifestations of preeclampsia are
considered to result from placental oxidative stress and
vascular damage because of the dysregulation of angiogenic
factors,33–36 we hypothesized that targeting inhibitors of
complement to the placenta would not only prevent placental
dysfunction but would also attenuate other features of
preeclampsia in CBA/JDBA/2 pregnancies. To investigate
this possibility, we administered CR2-Crry on day 5 of
pregnancy and measured urinary protein, BUN, and
examined renal tissue on day 15. Targeted complement
inhibition prevented renal lesions in CBA/JDBA/2 mice;
albumin/creatinine ratios, and BUN at day 15 were compar-
able with CBA/JBALB/c mice (Figure 1a and b).
Immunofluorescence staining of kidneys showed that the
increase in glomerular capillary wall and luminal deposits of
fibrin in CBA/JDBA/2 mice (mean fibrin score 1.5þ ;
range 1–2þ ) was markedly attenuated in mice treated with
CR2-Crry (fibrin score 0.75þ ; range 0.5–1þ ; Figure 1c).
Similarly, the endothelial cell swelling and areas of segmental
foot process evident by electron microscopy in kidneys of
CBA/JDBA/2 mice, were averted in pregnancies treated
with CR2-Crry (Figure 1d). The histologic changes in
glomeruli are not related to local activation of complement.
Immunofluorescence studies demonstrated minimal C3
(mainly in the interstitium) in kidneys of CBA/JDBA/2,
which did not differ from that in CBA/JBALB/c mice
(Figure 3, right panels). Taken together, our findings
demonstrate that blockade of complement activation targeted
exclusively to areas of complement activation is sufficient to
prevent maternal features of preeclampsia.
To confirm that complement inhibition prevents pre-
eclamptic renal injury and proteinuria, we used a second
strategy. We treated CBA/2DBA/J mice with a non-
targeted systemic complement inhibitor, anti-C5 monoclonal
antibody (mAb), that blocks cleavage of C5, a pivotal
complement component that generates two effectors, C5a, a
potent anaphylatoxin, and C5b, which initiates formation of
the C5b-9 membrane attack complex. We have previously
shown that C5a–C5a receptor interactions initiate angiogenic
dysregulation and placental dysfunction in abortion-prone
mice.10,37 Consistent with our findings using CR2-Crry, anti-
C5 mAb prevented proteinuria and decreased BUN in DBA/J-
mated CBA/2 mice (Figure 1a and b). Placental oxidative
Decidua Kidney
CBAxBALB
CBAxDBA
CBAxDBA
CR2-Crry
Figure 3 |Complement is activated in the deciduas but not in
the kidneys of CBA/JDBA/2 matings. Deciduas (left panel)
and kidneys (right panel) were isolated from pregnant mice on
day 8 or day 15, respectively. Deposition of C3 was examined by
immunofluorescence staining. In CBA/JDBA/2 mice, there was
extensive C3 deposition on trophoblasts in the developing
placenta, whereas only trace C3 staining was present in the
interstitium in all three groups. Mean C3 scores (range): Deciduas:
CBA/J BALB/c¼ 0.25þ (0–0.5þ ), CBA/JDBA/2¼ 2þ
(1–2.5þ ), and CBA/JDBA/2 with CR2-Crry¼ 0.5þ (0–1þ );
kidneys, CBA/J BALB/c¼ 0.5þ (0–1þ ), CBA/JDBA/2¼ 0.5þ
(0–1þ ), and CBA/JDBA/2 with CR2-Crry¼ 0.75þ (0.5–1þ ;
n¼ 4–6 mice per group). Magnification  400. CR2, complement
receptor type 2; Crry, CR2-related gene/protein y.
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stress was also reduced in anti-C5 mAb-treated mice
(placental STAT-8: control versus anti-C5 mAb 121±14
versus 77±43 pg/ml, n¼ 21 and 4 mice/group, respectively,
P¼ 0.057) supporting the concept that complement activa-
tion contributes to the placental injury that drives angiogenic
dysregulation and promotes a feed-forward loop that
culminates in fetal growth restriction or death and maternal
vascular damage.
Restoration of circulating VEGF prevents placental
dysfunction, pregnancy complications, and proteinuria in
CBA/JDBA/2 matings
Dysregulation of angiogenic factors presages preeclampsia in
humans, but interventions to reverse the imbalance are not
yet available.36,38 In DBA/J-mated CBA/2 mice, targeted
inhibitors of complement block the increase in sFlt-1. It was
not clear, however, whether correction of sFlt-1 excess, in and
of itself, is sufficient to prevent the features of preeclampsia
in this model. In a rat model of preeclampsia induced by
chronic reductions in uteroplacental perfusion pressure,
delivery of recombinant VEGF121 late in pregnancy reduced
hypertension and improved renal function, generated by
chronic elevations of sFlt-1.39,40 In contrast, CBA/JDBA/2
mice are not hypertensive and their placental dysfunction is
mediated by inflammation. To determine whether restoration
of circulating VEGF during the first half of pregnancy could
prevent features of preeclampsia, we administered VEGF121,
the most soluble of VEGF isoform, on days 3 through 10.
Treatment with VEGF121 reduced placental oxidative stress
assessed by STAT-8 on day 15 (Figure 4a), and prevented
proteinuria, elevated BUN (Figure 1a and b), and pregnancy
loss (Figures 4d), although fetal weights were not significantly
altered by VEGF121 treatment (control versus VEGF121:
288±3 versus 280±5 mg, n¼ 14–28, P¼not significant).
Treatment with VEFG121 seemed to decrease plasma sFlt-1
(Figure 4b), perhaps attributable to decreased capacity of
enzyme-linked immunosorbent assay to detect sFlt-1 com-
plexed to VEGF-121. Alternatively, increased available VEGF
may lead to enhanced placental perfusion resulting in
decreased sFlt-1 expression. That correction of angiogenic
imbalance, as well as blockade of complement activation at
the maternal–fetal interface, rescues placental and maternal
systemic features of preeclampsia supports a relationship
between these pathways.
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Figure 4 | Targeted inhibition of complement activation prevents oxidative stress and placental dysfunction in CBA/JDBA/2
matings. Female CBA/J mice were mated with male DBA/2 or BALB/c mice. Some pregnant DBA/2-mated CBA/J mice were treated
with CR2-Crry (200mg i.v. on day 5 of pregnancy), VEGF121 (4 mg s.c. daily from day 3 to day 10), or PBS as control. (a) Placental isoprostane
8-iso-prostaglandin F2a (STAT-8) levels measured on day 15 were higher in CBA/JDBA/2 mice. In mice treated with CR2-Crry, placental
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DISCUSSION
DBA/2-mated CBA/J mice have been studied as examples of
abortion related to abnormal maternal–fetal tolerance.41,42
We present the first evidence that these matings show some
systemic features of preeclampsia, specifically renal dysfunc-
tion. It has been proposed that factors released by the
immunologically injured, inflamed, and ischemic placenta
cause the clinical syndrome of preeclampsia,33,35,43 and such
factors have been the focus of studies in many experimental
animal models. Placental dysfunction has been induced by
reduced uterine perfusion, thrombotic diatheses, angiotensin
receptor agonistic autoantibodies, and by genetic deficiencies
of heme oxygenase, adrenomedullin, and catechol-O-methyl
transferase.35,40,44–47 Specific treatments for preeclampsia
have been proposed based on these models. CBA/2DBA/J
matings show similar evidence of placental dysfunction,
oxidative stress, activation of coagulation, elevated anti-
angiogenic factors, and fetal loss;10,23 and they manifest the
expected phenotype, maternal renal dysfunction, presenting
as proteinuria, endothelial cell swelling (endotheliosis), and
fibrin deposition in glomeruli. The current work is unique in
that it presents a treatment strategy directed at inflammation
in the developing placenta, rather than at the downstream
systemic mediators. We found no evidence of complement
activation in kidneys.
Complement activation at the maternal–fetal interface
early in abnormal pregnancies has been documented by our
group and others.10,48–51 Placental oxidative stress, character-
istic of experimental models of preeclampsia and the human
condition, and exaggerated hypoxia promote complement
activation and render tissue more susceptible to comple-
ment-mediated injury, perpetuating the vicious cycle.52 Local
generation of C5a triggers the release of sFlt-1 from
infiltrating inflammatory cells, and sFlt-1 impairs trophoblast
proliferation, reduces placental blood flow, and induces
ischemia that leads to increased placental sFlt-1 production.
We have previously shown that Crry-Ig, a potent inhibitor of
all complement activation pathways in mice (administered as
3 mg i.p. on days 4, 6, and 8 of pregnancy), rescues
miscarriage in CBA/JDBA/2 mice.10 However, the effects
of complement inhibition on placental oxidative stress or
renal dysfunction associated with angiogenic dysregulation
have not been examined. CR2-Crry had no significant effect
on serum complement activity and does not increase
susceptibility to infection,18 but we expected enhanced
bioavailability and therapeutic efficacy.17–19 That was indeed
the case, as administration of 0.2 mg i.v. on day 5 of
pregnancy (15-fold lower than the Crry-Ig dose and 45-fold
less total protein throughout pregnancy) provided equivalent
protection from fetal loss to that imparted by Crry-Ig, despite
a markedly shorter half-life.18 The single dose of CR2-Crry
prevented the increase in circulating sFlt-1 and the
consequent glomerular damage, fibrin deposition, and
proteinuria.
Release of sFlt-1 into the maternal circulation blocks
VEGF and placental growth factor, the trophic signals
required to maintain the renal filtration barrier, and leads
to a loss of integrity of this barrier and development of
proteinuria.4,38,40,53 Deletion of VEGF from podocytes in
mice promotes microvascular injury, microthrombotic an-
giopathy, and proteinuria and is followed by hypertension.53
In patients, VEGF inhibitors have similar effects, mild
proteinuria and, less commonly, hypertension; both are
transient and reversible, as in preeclampsia.9 In CBA/J
DBA/2 mice, elevated levels of sFlt-1 precede proteinuria,
but hypertension is not present. We speculated that the lack
of hypertension in this model is because of the relative
magnitude of elevation in sFlt-1 in CBA/JDBA/2 (nearly
threefold increase) is less than that described in animal
models of preeclampsia with hypertension which show at
least fivefold increase in sFlt-1.4,47 The phenocopy of
gestational proteinuria without hypertension, considered a
milder variant of human preeclampsia, was recently shown to
be associated with modest angiogenic imbalance, detectable
as early as 10–12 weeks of gestation.54 Administration of
excess VEGF121 to CBA/2DBA/J mice early in pregnancy
prevented placental oxidative stress, microthrombotic angio-
pathy, proteinuria, and pregnancy loss underscoring the
importance of angiogenic dysregulation in this model and its
relevance to the proposed pathophysiology of human
preeclampsia. That blockade of complement is as effective
as VEGF121 administration in averting the preeclampsia-like
phenotype and protecting pregnancy argues that local
complement activation is an early trigger of placental injury
that produces angiogenic dysregulation and ultimately drives
preeclampsia.
A role for complement activation in preeclampsia was
postulated nearly 20 years ago,11,55 but whether it was a cause
or consequence was unclear. Our findings in a new mouse
model prove that local complement activation is sufficient to
trigger placental and some maternal features of preeclampsia.
Evidence of alternative pathway activation in early pregnancy
in women more likely to develop preeclampsia argues that our
findings in CBA/JDBA/2 mice are relevant to patients.11,55
That low molecular weight heparin blocks activation of
complement in vivo and in mouse models and prevents
preeclampsia in some patients at high risk56 emphasizes the
importance of developing targeted complement inhibitors for
this disease.57 Our studies in CBA/JDBA/2 mice identify an
exciting new approach to limit morbidity and mortality in
human pregnancies at risk for preeclampsia.
METHODS
Timed breeding and treatment protocols
Female CBA/J (H2k), male DBA/2 (H2d), and BALB/c (H2d) mice
were purchased from the Jackson Laboratory (Bar Harbor, ME). All
animal studies were approved by the Institutional Animal Care and
Use Committee of the Hospital for Special Surgery or Weill Medical
College of Cornell University. Virgin female CBA/J mice (8- to 10-
week old) were mated with 10- to 12-week-old male DBA/2 or
BALB/c mice as previously described.10
To block complement activation during pregnancy, we used a
targeted complement inhibitor CR2-Crry. Recombinant CR2-Crry
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fusion protein prepared as previously described18 was injected on
day 5 of pregnancy (0.2 mg i.v.). To block C5 cleavage, a group of
mice was treated with an anti-C5 mAb (mouse immunoglobulin G1,
clone BB5.1, 1 mg/day i.p.) on days 4 and 6 of pregnancy as
previously described.10 To reverse the angiogenic dysregulation that
is characteristic of DBA/2-mated CBA/J mice, a group of mice was
treated with human VEGF121 (kindly provided by SA Karumanchi,
Beth Israel Deaconess Hospital; 4 mg s.c.) on days 3 to day 10 of
pregnancy.
Blood was collected to measure soluble Flt1, TAT, BUN,
and C3a. Urine was collected on day 15. Pregnant mice were killed
on day 15. Fetal resorption frequency was calculated as number of
resorption/total number of formed fetuses. Weights of viable fetuses
and placentas were recorded. Placentas collected to measure
isoprostane 8-iso-prostaglandin F2a (STAT-8), using a commercial
EIA kit (Cayman Chemical, Ann Arbor, MI).58 Kidneys
were harvested for immunohistochemical studies and light and
electron microscopy.
Plasma levels of sFlt-1 were determined by ELISA following
manufacturer’s instructions (R&D systems, Minneapolis, MN).
TAT levels were measured in sodium citrate plasma by ELISA
(Enzygnost TAT, Dade Behring, Deerfield, IL). To measure C3a,
plasma samples were collected in EDTA, stored at 80 1C and
assayed by ELISA. Plates coated with rat-anti-mouse C3a mAb
(clone I87-1162, BD Bioscience (San Jose, CA); 2 mg/ml) were
incubated with samples diluted in 1% bovine serum albumin/
phosphate-buffered saline. Biotin conjugated anti-C3a mAb was
used to detect plate-bound C3a, followed by incubations with
streptavidin–horseradish peroxidase and tetramethylbenzidine.
Urine albumin/creatinine ratio was determined with an Albuwell
M test kit and Creatinine Companion kit (Exocell, Philadelphia,
PA). BUN was examined with a Blood Urea Nitrogen kit (Pointe
Scientific, Canton, MI).
Morphologic studies
Kidneys from day 15 pregnant mice were harvested for morphologic
studies. For immunofluorescence studies, snap frozen deciduas or
kidneys were sectioned at 3 mm, washed with phosphate-buffered
saline and stained with fluorescein isothiocyanate-conjugated
polyclonal antifibrin antibody (Dako, Carpinteria, CA), or fluor-
escein isothiocyanate-conjugated anti-mouse C3 mAb (Cedarline,
Burlington, NC). Intensity of immunofluorescence was scored
semiquantitatively (on a scale of 0–3þ : 0 negative, 0.5 trace, 1
mild, 2 moderate, 3 marked). There were two to six mice studied for
each condition. For kidney studies, a total of 100 glomeruli per
mouse were scored and intensity was expressed as a mean (range).
Histology of kidneys was assessed by staining with hematoxylin
and eosin, as well as periodic acid-Schiff and Masson’s trichrome. In
each condition, two to five mice were studied.
Electron microscopy was examined under a JEOL 1011 electron
microscope (JEOL USA Inc, Peabody, MA) equipped with digital
imaging system. There were two to five mice studied for each
condition and a minimum of 10 glomeruli sampled per mouse.
Radiotelemetric measurement of blood pressure
Continuous measurement of blood pressure before, during and after
pregnancy was carried out as described previously.59 Briefly, a cohort
of CBA female mice were anesthetized and instrumented with
TA11PA-C10 radiotelemeters (Data Sciences International, Arden
Hills, MN). Mice were allowed to recover for 5 days before baseline
measurements were taken over 3 days. DBA/2 or BALB/c males were
placed in the cages for mating. After plug detection, blood pressure
was recorded in a 24 h scheduled mode as described previously..59,60
Statistical analysis
Data were first tested for normal distribution using Kolmogor-
ov–Smirnov test. Student’s t-test was used to compare differences in
means. Blood pressure data were analyzed using repeated measures
analysis of variance. Data are expressed as means±s.e.m. Statistical
analysis was performed using Graphpad Prism 5.0 statistical
software. Po0.05 was considered as statistically significant.
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